CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation
- 1 March 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 73 (3), 602-611
- https://doi.org/10.1161/hypertensionaha.118.11874
Abstract
Myocardial fibrosis is a main contributor to the development of heart failure (HF). CT-1 (cardiotrophin-1) and Gal-3 (galectin-3) are increased in HF and associated with myocardial fibrosis. The aim of this study is to analyze whether CT-1 regulates Gal-3. Proteomic analysis revealed that Gal-3 was upregulated by CT-1 in human cardiac fibroblasts in parallel with other profibrotic and proinflammatory markers. CT-1 upregulation of Gal-3 was mediated by ERK (extracellular signal-regulated kinase) 1/2 and Stat-3 (signal transducer and activator of transcription 3) pathways. Male Wistar rats and B6CBAF1 mice treated with CT-1 (20 µg/kg per day) presented higher cardiac Gal-3 levels and myocardial fibrosis. In CT-1–treated rats, direct correlations were found between cardiac CT-1 and Gal-3 levels, as well as between Gal-3 and perivascular fibrosis. Gal-3 genetic disruption in human cardiac fibroblasts and pharmacological Gal-3 inhibition in mice prevented the profibrotic and proinflammatory effects of CT-1. Dahl salt-sensitive hypertensive rats with diastolic dysfunction showed increased cardiac CT-1 and Gal-3 expression together with cardiac fibrosis and inflammation. CT-1 and Gal-3 directly correlated with myocardial fibrosis. In HF patients, myocardial and plasma CT-1 and Gal-3 were increased and directly correlated. In addition, HF patients with high CT-1 and Gal-3 plasma levels presented an increased risk of cardiovascular death. Our data suggest that CT-1 upregulates Gal-3 which, in turn, mediates the proinflammatory and profibrotic myocardial effects of CT-1. The elevation of both molecules in HF patients identifies a subgroup of patients with a higher risk of cardiovascular mortality. The CT-1/Gal-3 axis emerges as a candidate therapeutic target and a potential prognostic biomarker in HF.Keywords
This publication has 37 references indexed in Scilit:
- STAT1/3 and ERK1/2 Synergistically Regulate Cardiac Fibrosis Induced by High GlucoseCellular Physiology and Biochemistry, 2013
- Galectin-3 Mediates Aldosterone-Induced Vascular FibrosisArteriosclerosis, Thrombosis, and Vascular Biology, 2013
- Cardiotrophin 1 Is Involved in Cardiac, Vascular, and Renal Fibrosis and DysfunctionHypertension, 2012
- A role for cardiotrophin-1 in myocardial remodeling induced by aldosteroneAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fractionAnnals of Medicine, 2010
- Vascular effects of cardiotrophin-1: a role in hypertension?Journal of Hypertension, 2010
- Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: Potential diagnostic implicationsJournal of Hypertension, 2009
- Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart FailureJournal of the American College of Cardiology, 2006
- Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac DysfunctionCirculation, 2004
- Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive OriginCirculation, 2004